focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
This is an unpaid for advertisement for a rival share forum, which has been deposited on 250 LSE boards. The account, which set up the advertising, has been deleted. A cheeky way of achieving free advertising to communities with an interest in their product?
An ironic comment on their platform states:
“Filter out non verified users and have confidence that you're conversing with a real person, without a hidden agenda.”
Also, very recently so many diverse sources like this one are claiming to use AI in their products. It is too early stage for me, at present, but I am following developments with interest. I was surprised to find a book on the subject , published in 2023, on sale yesterday at a high street £4 book shop.
I apologise for not writing a comment relevant to Synairgen. Regrettably, until the company finally decides to update investors on their strategy, there is little more that anyone can add to what has already been stated.
GLALTIs
We are in need of a long overdue RNS affirming that SYME’s strategy is on track. The volume of trades at the current, obscenely low, level is disappointing. Especially so for LTIs who have been severely misled by the CEO’s confusing rhetoric.
It does look as though our esteemed (not) CEO, and his cabal of cronies are at it again. I am regarding my holding here less as an investment, but instead as a participation in a slush fund, benefiting a minority, and from which investors are excluded.
All the good work and positive messages from the hardworking IB staff are not being properly channeled. What we are witnessing here makes little sense, except perhaps to the small number of beneficiaries, who are effectively in control of the business’ share price.
It was good to receive this highly relevant ( to my investment, that is ) piece of news. Thanks to Brand for sharing.
I am hoping that it will serve as a harbinger to further positive information from Synairgen, and perhaps from another allied source at the same time.
It has been a very long wait, and this, to my mind, explains the silly comments that emerge on this forum from time to time. The only important aspect from here onwards is that Synairgen finally get a strategy on track and without further delays, or slip-ups.
GLALTIs.
1. A CDMO is a Contract Development and Manufacturing Organisation meaning they not only handle the outsourced manufacturing of drug substances, but also all of the innovation and development work that occurs prior to manufacturing one.
2. This means that small pharmaceutical companies no longer need to build and staff dedicated innovation and manufacturing facilities.
3. CDMOs can start with a concept or a READY-TO-GO FORMULA, with CLINICAL TRIALS and COMMERCIAL PRODUCTION services made available.
4. When pharmaceutical companies find the right CDMO, they gain flexibility, collaboration and innovation services to help increase speed to market and lower costs by providing expertise and equipment they don’t have in house.
5. CDMOs can accelerate drug development and improve pharmaceutical companies’ bottom lines.
6. Some idea of the growth and future trends in the CDMO market may be found in the following link:
https://www.businesswire.com/news/home/20220303005497/en/289.64-Billion-Pharmaceutical-Contract-Development-and-Manufacturing-Organization-CDMO-Markets-2027---ResearchAndMarkets.com
It seems to me that Synairgen might benefit from a mutually beneficial partnership with the right CDMO?
GLALTIs
Most LTIs have maintained or added to their Synairgen investment over the last two years, believing that SNG001's efficacy as a host directed broad spectrum anti viral treatment will eventually be proven through a series of trials.
Unfortunately our belief in a product, underpinned by a myriad of scientific evidence, is taking far longer than expected to being validated. I believe that Synairgen's executives have tried various means to achieve a way forward, but have been unsuccessful thus far.
Their reluctance to communicate with investors has resulted in our current situation. Synairgen is valued in line with its cash reserve. Consequently, the share price will continue to fall, unless the company can communicate something positive about its current strategy.
I resent the comments of contributors who dismiss the views of others by making silly accusations, as was the case with my contribution yesterday. Two attempts were made to deflect my original comment by challenging my position as a Synairgen investor? I see no logical reason for this? It only leads to further comments about the status of the individuals making these accusations.
The forum has been set up to offer investors a means of communicating about their investment. Unfortunately, Synargen's apparent lack of progress makes it difficult to sustain meaningful and relevant communication. My thanks to all who share tangentially relevant scientific insights relating to SNG001. Some are interesting to read, and help to maintain a belief that one day Synairgen's executives will have something positive to communicate.
GLALTIs.
Why would anyone object to selling shares @ 30p, and buying them back again @ 5p per share? I am envious of the smart investors, who managed to do just that. Following TFG's strategy was not so smart and I am poorer today as a result of doing so.
GLALTIs.
No Fruitsnveg, I merely agreed with a single point made both by Axe-Capital, and Manifesto concerning the timing of the long anticipated RNS. Nothing else.
I have agreed with some of your points in the past, and currently agree with TommyD_19 that there is a lot of nonsense being expressed on this forum owing to the dearth of information from the company over five months.
Surely it shouldn’t take in excess of two years to devise a recovery strategy for a moonshot product? Hence my comment about the quality of the company’s leadership team earlier today.
The multiple account nonsense is a diversionary tactic issued by a few “contributors”. This silly response is invariably made in defence of anything inappropriate, but apparently true, being expressed about Synairgen personnel.
Ironically, I have sometimes thought that there are different individuals attending these to these accounts, which makes their accusations so ironic.
Unfortunately, I too believe that Axe -Capital and Manifesto are correct.
The outstanding individuals in this company are the scientists, whose diligence, hard endeavour and brilliance resulted in SNG001.
Sadly, the executives that run the company are mediocre AIM-level directors at best. They are capable of going through the motions, and ticking boxes. They do what is necessary, nothing else. When they were put to the test, they failed miserably, and lacked the humility to acknowledge the fact.
I agree with Fruitsnveg that the company has a potential “moonshot” broad spectrum anti-viral product, which has been sitting on the shelf for two years. When I consider the extravagant expenditure, including board expenses, and executive pay deals and options, over the last two years, it makes me believe that a lot more should have been achieved in that time! Currently, the company is spending the residue of investor capital on P2 trials. Five months since their announcement, the CEO has lacked the basic courtesy of informing us how they are faring! No doubt, he will continue to wait until the last possible opportunity before informing us. Should it be yet another delay, he will confirm the very low opinion that a large number of investors hold as to his credibility.
GLALTIs.
Unfortunately, the “sell on the RNS bounce” narrative doesn’t work for far underwater LTIs. Good luck with that if it works for you.
Many of us, who believed in a successful P3 outcome just over two years ago, and have held and added since then, need a different exit. Personally, I require a significant multibagger to recover my original investment. This can only result from successful P2 outcomes, followed by a JV venture to take the treatment further.
I doubt whether a buyout, as some suggest, is a feasible outcome? Surely if this were a possible scenario, it would have been enacted earlier?
GLALTIs.
My previous comment is still valid, although if the CEO doesn’t issue a statement soon, his credibility with many investors will continue to wane. Two years is more than enough time for any credible company to table funded “concrete” proposals following a serious setback.
Mr. Marsden’s fuzzy rhetoric has prevailed for too long. New potential investors need hard facts and costings upon which to base their decisions.
As for LTIs, we are the long forgotten majority in the eyes of this company. It was our funding that enabled the last P3 trial, and its residue has enabled its well-rewarded executives to remain in situ since then. It is high time for Mr. Marsden to show LTIs more respect.
GLALTIs.
Trinityman.
It was good to read your recent salient points, and I was hopeful of your return as a regular contributor to this forum. Your detailed, well-researched, and thoughtful contributions invariably resonate positively with my own thoughts about this particular investment.
Equally, I was sorry to read about your health issue, and extend my support, and very best wishes as you recover to good health.
Take care, T_P.
BertieBassett,
This was my view also, following the orchestrated sequence that unfolded during the first two months of Q1.
Given the intrinsic value within the company, how long can certain parties continue with the ongoing fiasco that we have been treated to? Their self-rewarding strategy is so transparent, yet they persist with it, and are allowed to get away with it? Surely there won’t be yet another round of the same unsubtle tactics?
My personal approach will be to continue to hold through thick and thin, in anticipation of a worthwhile reward at the end? I seriously thought of selling at 5p+ in anticipation of subterfuge? However, that approach is based on tracking, and gambling on the greed of others. Probably not the best investment strategy, but a perfectly reasonable approach as it turned out in light of the way that long term IQAI investors have been treated!
GLALTIs.
No need to justify that comment Hallowed. It was obvious what you meant, especially for those of us who have been invested for 2 plus years.
Of course it is true that any small MCap company could go under. The only reason for being invested in SYME was due to the fact that it offered potentially high rewards, but at an associated high risk.
It may yet deliver? The fact is that the CEOs confusing comments have misled investors for quite a time doesn’t negate that there may yet be an upside from here?
Those of us who decide to remain invested will just have to wait and see? GLALTIs.
Interesting to note that a thread of five posts, including Trek’s earlier post have been removed? I do not believe that any regular contributor was responsible. Additionally, it isn’t the moderation team, as they rely on posts being reported by multiple readers.
Am I into conspiracy theory territory when I suspect that someone representing a certain individual didn’t enjoy reading some earlier comments? This being the case, a number of subsequent posts, which adopt a similar narrative, will also be removed?
Why is anyone selling middling (24,500000 shares) amount of stock for such a derisory price ( 0.0029p)? What do they hope to gain from this single transaction?
“£300,000 has been raised by the Company through the issue of 20,000,000 new Ordinary Shares (the "Placing Shares")”
It will be interesting whether or not a subsequent TR-1 will inform investors about the ownership of the 20m placing shares? Will the prime suspect choose to keep his suspected acquisition of 9% of the company for a derisory £300K hidden? This could easily be arranged via intermediaries. Nothing would surprise me following this underhand strategy, presumably designed to enrich a small group of well placed investors? No one is fooled by this, and I doubt whether the perpetrators are troubled by naive investors’ opinions’. Moreover, the so - called Broker Option of 4,733,333 shares seems like an arbitrary figure, which will no doubt mostly find itself in the portfolios of a small number of investors?
This entire scenario not only causes retail investors to lose trust in certain manipulative operators, but also in the way that these processes are enacted, apparently without any underpinning from a regulatory body?
I intend to exit from this investment once a break - even point is achieved. I remain hopeful of turning a small profit? However, one cannot be certain how many twists and turns lie ahead on what has proven to be a particularly crooked path?
GLALTIs.
We can endlessly speculate about future possibilities for our drug. Putting first things first, investors need to have some idea about the nature and timelines of the forthcoming trials?
It is only if and when these trials are successfully concluded that we will have some idea of the potential value of our investment ?
I have no disagreement with anybody’s speculation owing to my current dearth of information. However, I still recall my extreme disappointment of two years ago. Before that announcements there was wild speculation about Synairgen investors’ future prosperity. We all know what became of that total misjudgement of our trial outcome.
GLALTIs.
I agree that our drug has significant potential once the company is able to take it beyond successful P2 trialing. It is best to remain positive, until we are updated on Synairgen’s progress in getting these trials underway.
Perhaps, my strategy which closely mirrored that of TFG may yet prove to be fruitful? I intend to remain guardedly optimistic until we receive an update.